Evento

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

Bruni, SofiaIcon ; de Martino, MaraIcon ; Mauro, Florencia L.; Mercogliano, María FlorenciaIcon ; Proietti Anastasi, Cecilia JazmínIcon ; Cordo Russo, Rosalia InesIcon ; Elizalde, Patricia VirginiaIcon ; Schillaci, RoxanaIcon
Tipo del evento: Reunión
Nombre del evento: 37th Annual Meeting SITC
Fecha del evento: 08/11/2022
Institución Organizadora: Society for Immunotherapy of Cancer;
Título de la revista: Journal for Immunotherapy of Cancer
Editorial: BMJ Publishing Group
e-ISSN: 2051-1426
Idioma: Inglés
Clasificación temática:

Resumen

Trastuzumab resistance is an important clinical issue. Although a plethora of resistance mechanisms have been characterized, few have been shown to be actionable. We have demonstrated that soluble TNFα isoform (sTNFα) upregulates mucin 4 (MUC4) expression, which shields the trastuzumab epitope on HER2, hindering its therapeutic effect in vitro and in vivo [1,2].
Palabras clave: SOLUBLE TNF , SENSITIZES , HER2-POSITIVE , MUC4
 
Archivos asociados
Thumbnail
 
Tamaño: 72.80Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/264375
URL: https://jitc.bmj.com/content/10/Suppl_2/A914
DOI: http://dx.doi.org/10.1136/jitc-2022-SITC2022.0877
Colecciones
Eventos(IBYME)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression; 37th Annual Meeting SITC; Boston; Estados Unidos; 2022; A914-A914
Compartir
Altmétricas